Dr. Lugtenburg on Maintenance Rituximab in DLBCL

Video

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab (Rituxan) as maintenance therapy in patients with diffuse large B-cell lymphoma (DLBCL).

Options are expanding for patients with DLBCL, however discovering therapies to extend survival for those patients who achieve complete remission (CR) remains a challenge with 40% of patients still having relapsed or refractory disease after rituximab is added to CHOP, says Lugtenburg.

In the second randomization of a phase II study, investigators evaluated rituximab as maintenance therapy versus observation for patients who achieved CR after R-CHOP. At median follow up of 79.9 months, the 5‐year DFS rate was 79% with rituximab maintenance versus 74% with observation (HR, 0.83; 95% CI, 0.57‐1.19; P = 0.31), showing no statistically significant benefit with rituximab. Investigators could not identify another subgroup of patients who benefitted from maintenance therapy in the study, Lugtenberg concludes.

<<< 15th International Conference on Malignant Lymphoma

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.